Protocol for thyroid remnant ablation after recombinant TSH in thyroid carcinoma.
نویسندگان
چکیده
In some countries, in order to perform rhTSH-aided thyroid remnant ablation (TRA) after surgery, it is generally necessary to confirm that thyroidectomy has been almost complete. Otherwise, the nuclear medicine specialist will not administer a high radioiodine dose because it might be hazardous due to the possibility of thyroid remnant actinic thyroiditis. Considering this, it would be necessary to use two rhTSH kits (one for diagnostic purposes and the other one to administer the 131I dose). In this study, we used an alternative protocol for TRA with the use of one kit of rhTSH in twenty patients diagnosed with low risk papillary thyroid carcinoma. All patients had negative titers of anti-thyroglobulin antibodies. Successful thyroid remnant ablation was confirmed with an undetectable rhTSH stimulated thyroglobulin level (< 1 ng/ml) in all 20 patients between 8 to 12 months after radioiodine administration. The use of this protocol combining scintigraphy with the subsequent administration of a therapeutic dose following the administration of one kit of rhTSH would avoid the need of using 2 kits to perform the ablation and would decrease the costs associated with its use while significantly enhancing the quality of life of patients with thyroid cancer.
منابع مشابه
Recombinant TSH (Thyrogen®) for ablation of thyroid remnant tissue post-thyroidectomy for thyroid cancer
• I ablation of remnant thyroid tissue following a total or near-total thyroidectomy for thyroid cancer is carried out in the hypothyroid state to increase endogenous TSH release and thus promote uptake of radioodine into the remaining thyroid tissue. Usually thyroid replacement therapy has to be withheld from patients for 3 to 6 weeks before ablation in order to achieve an adequate TSH level. ...
متن کاملCost-Effectiveness of Using Recombinant Human Thyroid-Stimulating Hormone before Radioiodine Ablation for Thyroid Cancer: The Canadian Perspectivevhe_650
Objectives: Radioiodine ablation for the treatment of thyroid cancer is traditionally performed after preparing patients by inducing hypothyroidism. Exogenous stimulation of thyroid-stimulating hormone (TSH) using recombinant human TSH (rhTSH) avoids hypothyroidism and hastens the clearance of radioiodine from the patient. These advantages are achieved without jeopardizing the success rate of r...
متن کاملThyroid hormone replacement one day before 131I therapy in patients with well-differentiated thyroid cancer
Objective: The current study aimed to determine the efficacy of radioiodine-131 (131I) ablation therapy with thyroid hormone replacement one day before 131I administration in patients with well-differentiated thyroid cancer (DTC). Methods: This retrospective study included 29 patients who underwent 131I therapies twice for DTC during 6-12 months. Since all the patients obviously had residual l...
متن کاملIs it Possible to avoid rh-TSH test in Patientswith Differentiated Thyroid Carcinoma byUsing the Association between Ablation andSuppressive Thyroglobulin?
Background: The follow-up of differentiated thyroid cancers is based on neck ultrasonography and serum thyroglobulin assay (Tg), during l-T4 therapy and after recombinant human TSH administration; this test appears quite expensive, considering that only a small percentage of patients with undetectable Tg on TSH suppression therapy shows a response after TSH stimulation. Objectives: The aim of o...
متن کاملRecombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management
Radioiodine (RAI) ablation following thyroidectomy is standard of care treatment for patients with intermediate or high risk differentiated thyroid cancer. Traditionally, this has been achieved by forgoing thyroid hormone replacement postoperatively, allowing endogenous thyroid stimulating hormone (TSH) levels to rise. This rise in TSH provides the stimulus for RAI uptake by the thyroid remnant...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Medicina
دوره 69 1 Pt 2 شماره
صفحات -
تاریخ انتشار 2009